Last updated on December 2018

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site


Brief description of study

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum doublet induction chemotherapy.

Clinical Study Identifier: NCT03498521

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: MX39795 ...

S rlandet Sykehus Kristiansand
Kristiansand, Norway
  Connect »